Emerging mRNA Technology for Liver Disease Therapy
ACS Nano · 09.07.2024 · 18 (27) · 17378-17406
DOI: 10.1021/acsnano.4c02987 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Nano, online erschienen am 25.06.2024. Verfasst von Ji Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Institute of Translational Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing Universit…. Hauptthemen laut MEDLINE: RNA, Messenger, Liver Diseases. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 265 Literaturangaben. Gefördert von: Jiangsu Province Postdoctoral Science Foundation, National Key Research and Development Program of China, Shenzhen Fundamental Research Program.
Abstract (Originalsprache)
Liver diseases have consistently posed substantial challenges to global health. It is crucial to find innovative methods to effectively prevent and treat these diseases. In recent times, there has been an increasing interest in the use of mRNA formulations that accumulate in liver tissue for the treatment of hepatic diseases. In this review, we start by providing a detailed introduction to the mRNA technology. Afterward, we highlight types of liver diseases, discussing their causes, risks, and common therapeutic strategies. Additionally, we summarize the latest advancements in mRNA technology for the treatment of liver diseases. This includes systems based on hepatocyte growth factor, hepatitis B virus antibody, left-right determination factor 1, human hepatocyte nuclear factor α, interleukin-12, methylmalonyl-coenzyme A mutase, etc. Lastly, we provide an outlook on the potential of mRNA technology for the treatment of liver diseases, while also highlighting the various technical challenges that need to be addressed. Despite these difficulties, mRNA-based therapeutic strategies may change traditional treatment methods, bringing hope to patients with liver diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Institute of Translational Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China.
- Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
ORCID-Profile: Ji Wang, Zhiqiang Luo, Jinglin Wang, Yuanjin Zhao
Förderung
- Jiangsu Province Postdoctoral Science Foundation
- National Key Research and Development Program of China
- Shenzhen Fundamental Research Program
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
- Nanjing Medical Science and Technique Development Foundation
- Clinical Trials from Nanjing Drum Tower Hospital
Zitieren
APA
Wang, J., Fang, Y., Luo, Z., Wang, J., & Zhao, Y. (2024). Emerging mRNA Technology for Liver Disease Therapy. ACS Nano, 18(27), 17378-17406. https://doi.org/10.1021/acsnano.4c02987
Vancouver
Wang J, Fang Y, Luo Z, Wang J, Zhao Y. Emerging mRNA Technology for Liver Disease Therapy. ACS Nano. 2024;18(27):17378-17406. doi:10.1021/acsnano.4c02987
BibTeX
@article{Wang2024,
author = {Wang, Ji and Fang, Yile and Luo, Zhiqiang and Wang, Jinglin and Zhao, Yuanjin},
title = {Emerging mRNA Technology for Liver Disease Therapy},
journal = {ACS Nano},
year = {2024},
volume = {18},
number = {27},
pages = {17378--17406},
doi = {10.1021/acsnano.4c02987}
}
EUVIMED